Yazar "Mungan, Semra" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Exploring the impact of wearing-off phenomenon in ocrelizumab-treated multiple sclerosis patients: Insights from a comprehensive study
    (Elsevier Sci Ltd, 2024) Seferoglu, Meral; Tunc, Abdulkadir; Sivaci, Ali Ozhan; Uzuner, Gulnur Tekgol; Mungan, Semra; Inanc, Yilmaz; Yetkin, M. Fatih
    Background: Ocrelizumab (OCR) effectively modifies the disease course in multiple sclerosis (MS) patients but may cause a preinfusion wearing-off phenomenon (WoP). This study explored the prevalence, timing, and severity of this phenomenon in MS patients using the OCR, as well as the associated symptoms and treatment satisfaction. Methods: We conducted a prospective multicenter study across 11 MS centers involving MS patients aged 18-70 years who had received at least two OCR doses. The study employed a questionnaire addressing demographic, clinical, and radiological data; symptom progression; and treatment satisfaction. Results: Of the 409 patients included in the study, 406 participated. A significant portion experienced varying degrees of WoP: 39.2% sometimes, 25.9% usually, and 14.3% always, with 55.9% noting symptom onset over four weeks prior to their next dose. Common symptoms included fatigue, walking difficulties, and pain. Subgroup analysis of 334 patients revealed that 78.1% of patients experienced these effects, which correlated with shorter disease durations, a longer delay between the two doses before the last dose, and a greater rate of relapse (P>0.05). Conclusion: The WoP of the OCR is prevalent and significant among MS patients and is influenced by the dosing interval, disease duration, and relapse rate. These insights underscore the need for personalized treatment schedules and more research into factors affecting MS management.
  • Küçük Resim
    Öğe
    Exploring the Impact of Wearing-Off Phenomenon in Ocrelizumab-Treated Multiple Sclerosis Patients: Insights from a Comprehensive Study
    (Sage Publications Ltd, 2024) Seferoglu, Meral; Tunc, Abdulkadir; Aksoy, Selma; Sivaci, Ali Ozhan; Uzuner, Gulnur; Mungan, Semra; Inanc, Yilmaz; Yetkin, Mehmet
    [Anstract Not Available]
  • [ X ]
    Öğe
    [Multipl sklerozda serum lipitleri ve Lp-PLa2 aktivitesi]
    (2014) Doğan, Halef Okan; Yılmaz, Fatma Meriç; Uysal, Sema; Mungan, Semra; Ak, Fikri
    Amaç: Multipl skleroz (MS) nedeni bilinmeyen inflamatuvar demiyelizan bir hastalıktır. Dislipidemi, T lenfosit aracılı inflamasyon, lipoprotein aracılı oksidatif aktivite ve lipoprotein ilişkili fosfolipaz A2 (Lp-PLA2) aktivitesi hastalığın patogenezinde rol almaktadır. Bu çalışmada farklı klinik dönemlerde olan MS hastalarında Lp-PLA2 aktivitesi ve serum lipit düzeyleri incelenerek hastalığın ilerleyişi üzerindeki etkilerinin ortaya konması amaçlanmıştır.Metod: Çalışmaya 30 hasta ve 30 kontrol dahil edildi. Kontrol ve hasta grupları Lp-PLA2 aktivitesi, total kolesterol, trigliserid, HDL kolesterol (HDL-K), LDL kolesterol (LDL-K), plazma aterojenik indeks (PAİ), non HDL-K ve total kolesterol/HDL-K düzeyleri yönünden karşılaştırıldı. Ayrıca hastalar klinik durumlarına göre gruplandırıldı ve gruplar Lp-PLA2 aktivitesi, total kolesterol, trigliserid, LDL-K ve HDL-K düzeyleri yönünden karşılaştırıldı.Bulgular: Hasta ve kontrol grupları arasında Lp-PLA2 aktivitesi, total kolesterol, trigliserid, HDL-K, LDL-K, PAİ, non-HDL-K ve total kolesterol/HDL-K düzeyi yönünden herhangi bir farka rastlanmadı. Buna ilave olarak klinik durumlarına göre gruplandırılan hastalar arasında Lp-PLA2 aktivitesi, total kolesterol, trigliserid, HDL-K ve LDL-K düzeyleri yönünden anlamlı herhangi bir fark yoktu. Sonuç: Serum lipit düzeyleri ve Lp-PLA2 aktivitesinin MS hastalığında ve hastalığın ilerleyişinde rol oynamadığı düşünülmektedir. Bu nedenle serum lipid ve LP-PLA2 düzeylerini düşürücü tedavi stratejilerinin hastalığın oluşumu, ilerleyişi ve vasküler olayların önlenmesinde önemli bir katkı sağlamayacağı düşünülmektedir.
  • [ X ]
    Öğe
    The Predictive Role of Neurobiochemical Markers in Multiple Sclerosis
    (Istanbul Training & Research Hospital, 2020) Oguz, Esra Firat; Mungan, Semra; Yilmaz, Fatma Meric; Ercan, Mujgan; Uysal, Sema
    Introduction: Multiple sclerosis (MS) is the most common, chronic, inflammatory, demyelinating disease of the central nervous system. We aimed to evaluate the levels of some neurobiochemical markers in order to evaluate their predictive role in MS. Methods: Fifty-one patients with a diagnosis of MS and 37 healthy subjects were included in the study. The patients with MS were diagnosed by a skilled neurologist based on the medical history and physical examination according to revised McDonald criteria. Neuron-specific enolase (NSE) and S100B levels were measured by electrochemiluminescence immunoassay. Glial fibrillary acidic protein (GFAP) and myelin basic protein (MBP) were measured by quantitive sandwich enzyme immunoassay technique with a commercially available ELISA kit. Results: There was a significant difference in NSE levels between the patient and the control groups. No significant difference was determined between the patient and the control groups in terms of S10013, MBP, and GFAP levels. S100B levels were positively correlated with Expanded Disability Status scale scores. Conclusion: Our findings indicated that NSE levels are significantly lower in MS patients. However, NSE levels should not be used alone at discriminating the disease. Multifactorial evaluation should be done during the diagnosis and follow-up of MS.